<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35189010</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1468-1331</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of neurology</Title>
          <ISOAbbreviation>Eur J Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical characteristics and outcome of neurosarcoidosis-associated myelitis: A retrospective cohort study and review of the literature.</ArticleTitle>
        <Pagination>
          <StartPage>1763</StartPage>
          <EndPage>1770</EndPage>
          <MedlinePgn>1763-1770</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15295</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">Neurosarcoidosis can affect all parts of the nervous system of which myelitis is relatively frequent. The aim of this study was to describe clinical characteristics, treatment and prognosis of patients with myelitis attributable to neurosarcoidosis.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective cohort study and a systematic review and meta-analysis of neurosarcoidosis-associated myelitis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Myelitis was identified in 41 of 153 (27%) neurosarcoidosis patients seen at our clinic from 2015 to 2020. Classification of neurosarcoidosis was definite in three (7%), probable in 29 (71%) and possible in nine patients (22%). The median (interquartile range) age at onset was 49 (41-53) years and 20 of the patients were female (49%). The presenting symptoms included muscle weakness in 31 of 41 patients (78%), sensory loss in 35 (88%) and micturition abnormalities in 30 (75%). Spinal magnetic resonance imaging showed longitudinally extensive myelitis in 27 of 36 patients (75%) and cerebrospinal fluid examination showed an elevated leukocyte count in 21 patients (81%). Initial treatment consisted of glucocorticoids in 38 of 41 patients (93%), with additional methotrexate or azathioprine in 21 of 41 patients (51%) and infliximab in 10 of 41 patients (24%). Treatment led to remission, improvement or stabilization of disease in 37 of 39 patients (95%). Despite treatment, 18 of 30 patients (60%) could not walk independently at the end of follow-up (median 36 months). A review of the literature published between 2000 and 2020 identified 215 patients with comparable clinical characteristics and results of ancillary investigations.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Sarcoidosis-associated myelitis is observed in 27% of neurosarcoidosis patients. Although treatment often led to a decrease in disease activity, residual neurological deficits leading to loss of ambulation occurred frequently.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nolte</LastName>
            <ForeName>Jessica Y C</ForeName>
            <Initials>JYC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ten Dam</LastName>
            <ForeName>Leroy</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0003-0505-5847</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van de Beek</LastName>
            <ForeName>Diederik</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brouwer</LastName>
            <ForeName>Matthijs C</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Eur J Neurol</MedlineTA>
        <NlmUniqueID>9506311</NlmUniqueID>
        <ISSNLinking>1351-5101</ISSNLinking>
      </MedlineJournalInfo>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C535814">Neurosarcoidosis</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002493" MajorTopicYN="Y">Central Nervous System Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009187" MajorTopicYN="Y">Myelitis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012507" MajorTopicYN="Y">Sarcoidosis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">autoimmune disease</Keyword>
        <Keyword MajorTopicYN="N">neurosarcoidosis</Keyword>
        <Keyword MajorTopicYN="N">spinal cord</Keyword>
        <Keyword MajorTopicYN="N">transverse myelitis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>21</Day>
          <Hour>17</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35189010</ArticleId>
        <ArticleId IdType="doi">10.1111/ene.15295</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet. 2014;383:1155-1167.</Citation>
        </Reference>
        <Reference>
          <Citation>Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016;16:220.</Citation>
        </Reference>
        <Reference>
          <Citation>Stern BJ, Royal W 3rd, Gelfand JM, et al. Definition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis consortium consensus group. JAMA Neurol. 2018;75:1546-1553.</Citation>
        </Reference>
        <Reference>
          <Citation>Zalewski NL, Krecke KN, Weinshenker BG, et al. Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology. 2016;87:743-744.</Citation>
        </Reference>
        <Reference>
          <Citation>Murphy OC, Salazar-Camelo A, Jimenez JA, et al. Clinical and MRI phenotypes of sarcoidosis-associated myelopathy. Neurol Neuroimmunol Neuroinflamm. 2020;7:e722.</Citation>
        </Reference>
        <Reference>
          <Citation>Soni N, Bathla G, Pillenahalli MR. Imaging findings in spinal sarcoidosis: a report of 18 cases and review of the current literature. Neuroradiol J. 2019;32:17-28.</Citation>
        </Reference>
        <Reference>
          <Citation>Durel CA, Marignier R, Maucort-Boulch D, et al. Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 BIOPSY-PROVEN patients. J Neurol. 2016;263:981-990.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang L, Li Y. Longitudinal ultra-extensive transverse myelitis as a manifestation of neurosarcoidosis. J Neurol Sci. 2015;355:64-67.</Citation>
        </Reference>
        <Reference>
          <Citation>Sohn M, Culver DA, Judson MA, Scott TF, Tavee J, Nozaki K. Spinal cord neurosarcoidosis. Am J Med Sci. 2014;347:195-198.</Citation>
        </Reference>
        <Reference>
          <Citation>Sakushima K, Yabe I, Nakano F, et al. Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients. J Neurol. 2011;258:2163-2167.</Citation>
        </Reference>
        <Reference>
          <Citation>Lidar M, Dori A, Levy Y, Lidar Z, Chapman J, Langevitz P. Sarcoidosis presenting as "corset-like" myelopathy: a description of six cases and literature review. Clin Rev Allergy Immunol. 2010;38:270-275.</Citation>
        </Reference>
        <Reference>
          <Citation>Kobayashi S, Nakata W, Sugimoto H. Spinal magnetic resonance imaging manifestations at neurological onset in Japanese patients with spinal cord sarcoidosis. Intern Med. 2013;52:2041-2050.</Citation>
        </Reference>
        <Reference>
          <Citation>Cohen-Aubart F, Galanaud D, Grabli D, et al. Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore). 2010;89:133-140.</Citation>
        </Reference>
        <Reference>
          <Citation>Varron L, Broussolle C, Candessanche JP, et al. Spinal cord sarcoidosis: report of seven cases. Eur J Neurol. 2009;16:289-296.</Citation>
        </Reference>
        <Reference>
          <Citation>Saleh S, Saw C, Marzouk K, Sharma O. Sarcoidosis of the spinal cord: literature review and report of eight cases. J Natl Med Assoc. 2006;98:965-976.</Citation>
        </Reference>
        <Reference>
          <Citation>Bradley DA, Lower EE, Baughman RP. Diagnosis and management of spinal cord sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23:58-65.</Citation>
        </Reference>
        <Reference>
          <Citation>Jacob A, Weinshenker BG. An approach to the diagnosis of acute transverse myelitis. Semin Neurol. 2008;28:105-120.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith E, Jaakonmäki N, Nylund M, Kupila L, Matilainen M, Airas L. Frequency and etiology of acute transverse myelitis in Southern Finland. Mult Scler Relat Disord. 2020;46:102562.</Citation>
        </Reference>
        <Reference>
          <Citation>Eurelings LEM, Miedema JR, Dalm V, et al. Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis. PLoS One. 2019;14:e0223897.</Citation>
        </Reference>
        <Reference>
          <Citation>Otto C, Wengert O, Unterwalder N, Meisel C, Ruprecht K. Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e725.</Citation>
        </Reference>
        <Reference>
          <Citation>Fritz D, van de Beek D, Brouwer MC, Booij J. Whole-body 18F-FDG PET-CT in the diagnosis of neurosarcoidosis. Mayo Clin Proc. 2020;95:1082-1084.</Citation>
        </Reference>
        <Reference>
          <Citation>Fritz D, Timmermans WMC, van Laar JAM, et al. Infliximab treatment in pathology-confirmed neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e847.</Citation>
        </Reference>
        <Reference>
          <Citation>Annunziata P, Masi G, Cioni C, et al. Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. Neurol Sci. 2019;40:1383-1391.</Citation>
        </Reference>
        <Reference>
          <Citation>Sepúlveda M, Blanco Y, Rovira A, et al. Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Mult Scler. 2013;19:742-748.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35189010</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1468-1331</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of neurology</Title>
          <ISOAbbreviation>Eur J Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical characteristics and outcome of neurosarcoidosis-associated myelitis: A retrospective cohort study and review of the literature.</ArticleTitle>
        <Pagination>
          <StartPage>1763</StartPage>
          <EndPage>1770</EndPage>
          <MedlinePgn>1763-1770</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15295</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">Neurosarcoidosis can affect all parts of the nervous system of which myelitis is relatively frequent. The aim of this study was to describe clinical characteristics, treatment and prognosis of patients with myelitis attributable to neurosarcoidosis.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective cohort study and a systematic review and meta-analysis of neurosarcoidosis-associated myelitis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Myelitis was identified in 41 of 153 (27%) neurosarcoidosis patients seen at our clinic from 2015 to 2020. Classification of neurosarcoidosis was definite in three (7%), probable in 29 (71%) and possible in nine patients (22%). The median (interquartile range) age at onset was 49 (41-53) years and 20 of the patients were female (49%). The presenting symptoms included muscle weakness in 31 of 41 patients (78%), sensory loss in 35 (88%) and micturition abnormalities in 30 (75%). Spinal magnetic resonance imaging showed longitudinally extensive myelitis in 27 of 36 patients (75%) and cerebrospinal fluid examination showed an elevated leukocyte count in 21 patients (81%). Initial treatment consisted of glucocorticoids in 38 of 41 patients (93%), with additional methotrexate or azathioprine in 21 of 41 patients (51%) and infliximab in 10 of 41 patients (24%). Treatment led to remission, improvement or stabilization of disease in 37 of 39 patients (95%). Despite treatment, 18 of 30 patients (60%) could not walk independently at the end of follow-up (median 36 months). A review of the literature published between 2000 and 2020 identified 215 patients with comparable clinical characteristics and results of ancillary investigations.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Sarcoidosis-associated myelitis is observed in 27% of neurosarcoidosis patients. Although treatment often led to a decrease in disease activity, residual neurological deficits leading to loss of ambulation occurred frequently.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nolte</LastName>
            <ForeName>Jessica Y C</ForeName>
            <Initials>JYC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ten Dam</LastName>
            <ForeName>Leroy</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0003-0505-5847</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van de Beek</LastName>
            <ForeName>Diederik</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brouwer</LastName>
            <ForeName>Matthijs C</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Eur J Neurol</MedlineTA>
        <NlmUniqueID>9506311</NlmUniqueID>
        <ISSNLinking>1351-5101</ISSNLinking>
      </MedlineJournalInfo>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C535814">Neurosarcoidosis</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002493" MajorTopicYN="Y">Central Nervous System Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009187" MajorTopicYN="Y">Myelitis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012507" MajorTopicYN="Y">Sarcoidosis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">autoimmune disease</Keyword>
        <Keyword MajorTopicYN="N">neurosarcoidosis</Keyword>
        <Keyword MajorTopicYN="N">spinal cord</Keyword>
        <Keyword MajorTopicYN="N">transverse myelitis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>21</Day>
          <Hour>17</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35189010</ArticleId>
        <ArticleId IdType="doi">10.1111/ene.15295</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet. 2014;383:1155-1167.</Citation>
        </Reference>
        <Reference>
          <Citation>Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016;16:220.</Citation>
        </Reference>
        <Reference>
          <Citation>Stern BJ, Royal W 3rd, Gelfand JM, et al. Definition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis consortium consensus group. JAMA Neurol. 2018;75:1546-1553.</Citation>
        </Reference>
        <Reference>
          <Citation>Zalewski NL, Krecke KN, Weinshenker BG, et al. Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology. 2016;87:743-744.</Citation>
        </Reference>
        <Reference>
          <Citation>Murphy OC, Salazar-Camelo A, Jimenez JA, et al. Clinical and MRI phenotypes of sarcoidosis-associated myelopathy. Neurol Neuroimmunol Neuroinflamm. 2020;7:e722.</Citation>
        </Reference>
        <Reference>
          <Citation>Soni N, Bathla G, Pillenahalli MR. Imaging findings in spinal sarcoidosis: a report of 18 cases and review of the current literature. Neuroradiol J. 2019;32:17-28.</Citation>
        </Reference>
        <Reference>
          <Citation>Durel CA, Marignier R, Maucort-Boulch D, et al. Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 BIOPSY-PROVEN patients. J Neurol. 2016;263:981-990.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang L, Li Y. Longitudinal ultra-extensive transverse myelitis as a manifestation of neurosarcoidosis. J Neurol Sci. 2015;355:64-67.</Citation>
        </Reference>
        <Reference>
          <Citation>Sohn M, Culver DA, Judson MA, Scott TF, Tavee J, Nozaki K. Spinal cord neurosarcoidosis. Am J Med Sci. 2014;347:195-198.</Citation>
        </Reference>
        <Reference>
          <Citation>Sakushima K, Yabe I, Nakano F, et al. Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients. J Neurol. 2011;258:2163-2167.</Citation>
        </Reference>
        <Reference>
          <Citation>Lidar M, Dori A, Levy Y, Lidar Z, Chapman J, Langevitz P. Sarcoidosis presenting as "corset-like" myelopathy: a description of six cases and literature review. Clin Rev Allergy Immunol. 2010;38:270-275.</Citation>
        </Reference>
        <Reference>
          <Citation>Kobayashi S, Nakata W, Sugimoto H. Spinal magnetic resonance imaging manifestations at neurological onset in Japanese patients with spinal cord sarcoidosis. Intern Med. 2013;52:2041-2050.</Citation>
        </Reference>
        <Reference>
          <Citation>Cohen-Aubart F, Galanaud D, Grabli D, et al. Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore). 2010;89:133-140.</Citation>
        </Reference>
        <Reference>
          <Citation>Varron L, Broussolle C, Candessanche JP, et al. Spinal cord sarcoidosis: report of seven cases. Eur J Neurol. 2009;16:289-296.</Citation>
        </Reference>
        <Reference>
          <Citation>Saleh S, Saw C, Marzouk K, Sharma O. Sarcoidosis of the spinal cord: literature review and report of eight cases. J Natl Med Assoc. 2006;98:965-976.</Citation>
        </Reference>
        <Reference>
          <Citation>Bradley DA, Lower EE, Baughman RP. Diagnosis and management of spinal cord sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23:58-65.</Citation>
        </Reference>
        <Reference>
          <Citation>Jacob A, Weinshenker BG. An approach to the diagnosis of acute transverse myelitis. Semin Neurol. 2008;28:105-120.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith E, Jaakonmäki N, Nylund M, Kupila L, Matilainen M, Airas L. Frequency and etiology of acute transverse myelitis in Southern Finland. Mult Scler Relat Disord. 2020;46:102562.</Citation>
        </Reference>
        <Reference>
          <Citation>Eurelings LEM, Miedema JR, Dalm V, et al. Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis. PLoS One. 2019;14:e0223897.</Citation>
        </Reference>
        <Reference>
          <Citation>Otto C, Wengert O, Unterwalder N, Meisel C, Ruprecht K. Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e725.</Citation>
        </Reference>
        <Reference>
          <Citation>Fritz D, van de Beek D, Brouwer MC, Booij J. Whole-body 18F-FDG PET-CT in the diagnosis of neurosarcoidosis. Mayo Clin Proc. 2020;95:1082-1084.</Citation>
        </Reference>
        <Reference>
          <Citation>Fritz D, Timmermans WMC, van Laar JAM, et al. Infliximab treatment in pathology-confirmed neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e847.</Citation>
        </Reference>
        <Reference>
          <Citation>Annunziata P, Masi G, Cioni C, et al. Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. Neurol Sci. 2019;40:1383-1391.</Citation>
        </Reference>
        <Reference>
          <Citation>Sepúlveda M, Blanco Y, Rovira A, et al. Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Mult Scler. 2013;19:742-748.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35189010</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1468-1331</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of neurology</Title>
          <ISOAbbreviation>Eur J Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical characteristics and outcome of neurosarcoidosis-associated myelitis: A retrospective cohort study and review of the literature.</ArticleTitle>
        <Pagination>
          <StartPage>1763</StartPage>
          <EndPage>1770</EndPage>
          <MedlinePgn>1763-1770</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15295</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">Neurosarcoidosis can affect all parts of the nervous system of which myelitis is relatively frequent. The aim of this study was to describe clinical characteristics, treatment and prognosis of patients with myelitis attributable to neurosarcoidosis.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective cohort study and a systematic review and meta-analysis of neurosarcoidosis-associated myelitis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Myelitis was identified in 41 of 153 (27%) neurosarcoidosis patients seen at our clinic from 2015 to 2020. Classification of neurosarcoidosis was definite in three (7%), probable in 29 (71%) and possible in nine patients (22%). The median (interquartile range) age at onset was 49 (41-53) years and 20 of the patients were female (49%). The presenting symptoms included muscle weakness in 31 of 41 patients (78%), sensory loss in 35 (88%) and micturition abnormalities in 30 (75%). Spinal magnetic resonance imaging showed longitudinally extensive myelitis in 27 of 36 patients (75%) and cerebrospinal fluid examination showed an elevated leukocyte count in 21 patients (81%). Initial treatment consisted of glucocorticoids in 38 of 41 patients (93%), with additional methotrexate or azathioprine in 21 of 41 patients (51%) and infliximab in 10 of 41 patients (24%). Treatment led to remission, improvement or stabilization of disease in 37 of 39 patients (95%). Despite treatment, 18 of 30 patients (60%) could not walk independently at the end of follow-up (median 36 months). A review of the literature published between 2000 and 2020 identified 215 patients with comparable clinical characteristics and results of ancillary investigations.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Sarcoidosis-associated myelitis is observed in 27% of neurosarcoidosis patients. Although treatment often led to a decrease in disease activity, residual neurological deficits leading to loss of ambulation occurred frequently.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nolte</LastName>
            <ForeName>Jessica Y C</ForeName>
            <Initials>JYC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ten Dam</LastName>
            <ForeName>Leroy</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0003-0505-5847</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van de Beek</LastName>
            <ForeName>Diederik</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brouwer</LastName>
            <ForeName>Matthijs C</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Eur J Neurol</MedlineTA>
        <NlmUniqueID>9506311</NlmUniqueID>
        <ISSNLinking>1351-5101</ISSNLinking>
      </MedlineJournalInfo>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C535814">Neurosarcoidosis</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002493" MajorTopicYN="Y">Central Nervous System Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009187" MajorTopicYN="Y">Myelitis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012507" MajorTopicYN="Y">Sarcoidosis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">autoimmune disease</Keyword>
        <Keyword MajorTopicYN="N">neurosarcoidosis</Keyword>
        <Keyword MajorTopicYN="N">spinal cord</Keyword>
        <Keyword MajorTopicYN="N">transverse myelitis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>21</Day>
          <Hour>17</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35189010</ArticleId>
        <ArticleId IdType="doi">10.1111/ene.15295</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet. 2014;383:1155-1167.</Citation>
        </Reference>
        <Reference>
          <Citation>Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016;16:220.</Citation>
        </Reference>
        <Reference>
          <Citation>Stern BJ, Royal W 3rd, Gelfand JM, et al. Definition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis consortium consensus group. JAMA Neurol. 2018;75:1546-1553.</Citation>
        </Reference>
        <Reference>
          <Citation>Zalewski NL, Krecke KN, Weinshenker BG, et al. Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology. 2016;87:743-744.</Citation>
        </Reference>
        <Reference>
          <Citation>Murphy OC, Salazar-Camelo A, Jimenez JA, et al. Clinical and MRI phenotypes of sarcoidosis-associated myelopathy. Neurol Neuroimmunol Neuroinflamm. 2020;7:e722.</Citation>
        </Reference>
        <Reference>
          <Citation>Soni N, Bathla G, Pillenahalli MR. Imaging findings in spinal sarcoidosis: a report of 18 cases and review of the current literature. Neuroradiol J. 2019;32:17-28.</Citation>
        </Reference>
        <Reference>
          <Citation>Durel CA, Marignier R, Maucort-Boulch D, et al. Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 BIOPSY-PROVEN patients. J Neurol. 2016;263:981-990.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang L, Li Y. Longitudinal ultra-extensive transverse myelitis as a manifestation of neurosarcoidosis. J Neurol Sci. 2015;355:64-67.</Citation>
        </Reference>
        <Reference>
          <Citation>Sohn M, Culver DA, Judson MA, Scott TF, Tavee J, Nozaki K. Spinal cord neurosarcoidosis. Am J Med Sci. 2014;347:195-198.</Citation>
        </Reference>
        <Reference>
          <Citation>Sakushima K, Yabe I, Nakano F, et al. Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients. J Neurol. 2011;258:2163-2167.</Citation>
        </Reference>
        <Reference>
          <Citation>Lidar M, Dori A, Levy Y, Lidar Z, Chapman J, Langevitz P. Sarcoidosis presenting as "corset-like" myelopathy: a description of six cases and literature review. Clin Rev Allergy Immunol. 2010;38:270-275.</Citation>
        </Reference>
        <Reference>
          <Citation>Kobayashi S, Nakata W, Sugimoto H. Spinal magnetic resonance imaging manifestations at neurological onset in Japanese patients with spinal cord sarcoidosis. Intern Med. 2013;52:2041-2050.</Citation>
        </Reference>
        <Reference>
          <Citation>Cohen-Aubart F, Galanaud D, Grabli D, et al. Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore). 2010;89:133-140.</Citation>
        </Reference>
        <Reference>
          <Citation>Varron L, Broussolle C, Candessanche JP, et al. Spinal cord sarcoidosis: report of seven cases. Eur J Neurol. 2009;16:289-296.</Citation>
        </Reference>
        <Reference>
          <Citation>Saleh S, Saw C, Marzouk K, Sharma O. Sarcoidosis of the spinal cord: literature review and report of eight cases. J Natl Med Assoc. 2006;98:965-976.</Citation>
        </Reference>
        <Reference>
          <Citation>Bradley DA, Lower EE, Baughman RP. Diagnosis and management of spinal cord sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23:58-65.</Citation>
        </Reference>
        <Reference>
          <Citation>Jacob A, Weinshenker BG. An approach to the diagnosis of acute transverse myelitis. Semin Neurol. 2008;28:105-120.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith E, Jaakonmäki N, Nylund M, Kupila L, Matilainen M, Airas L. Frequency and etiology of acute transverse myelitis in Southern Finland. Mult Scler Relat Disord. 2020;46:102562.</Citation>
        </Reference>
        <Reference>
          <Citation>Eurelings LEM, Miedema JR, Dalm V, et al. Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis. PLoS One. 2019;14:e0223897.</Citation>
        </Reference>
        <Reference>
          <Citation>Otto C, Wengert O, Unterwalder N, Meisel C, Ruprecht K. Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e725.</Citation>
        </Reference>
        <Reference>
          <Citation>Fritz D, van de Beek D, Brouwer MC, Booij J. Whole-body 18F-FDG PET-CT in the diagnosis of neurosarcoidosis. Mayo Clin Proc. 2020;95:1082-1084.</Citation>
        </Reference>
        <Reference>
          <Citation>Fritz D, Timmermans WMC, van Laar JAM, et al. Infliximab treatment in pathology-confirmed neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e847.</Citation>
        </Reference>
        <Reference>
          <Citation>Annunziata P, Masi G, Cioni C, et al. Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. Neurol Sci. 2019;40:1383-1391.</Citation>
        </Reference>
        <Reference>
          <Citation>Sepúlveda M, Blanco Y, Rovira A, et al. Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Mult Scler. 2013;19:742-748.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
